Drug Type Small molecule drug |
Synonyms (+)-vitamin D3, (3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol, (5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-trien-3-ol + [29] |
Target |
Mechanism VDR agonists(Vitamin D receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CA (01 Jan 1985), |
Regulation- |
Molecular FormulaC27H44O |
InChIKeyQYSXJUFSXHHAJI-YRZJJWOYSA-N |
CAS Registry67-97-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00188 | Colecalciferol |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Vitamin D Deficiency | CN | 01 Jan 1987 | |
Familial Hypophosphatemic Rickets | CA | - | 01 Jan 1985 |
Hypoparathyroidism | CA | - | 01 Jan 1985 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lower urinary tract infectious disease | Phase 2 | CN | 08 May 2021 | |
Insulin Resistance | Discovery | JO | 01 Feb 2014 | |
Overweight | Discovery | JO | 01 Feb 2014 | |
Polycystic Ovary Syndrome | Discovery | JO | 01 Feb 2014 | |
Vitamin D Deficiency | Discovery | JO | 01 Feb 2014 | |
Osteoporosis, Postmenopausal | Discovery | KR | 01 Dec 2011 | |
Chronic heart failure | Discovery | IT | 01 Nov 2011 | |
Asthma | Discovery | QA | 01 Feb 2011 | |
Sarcopenia | Discovery | US | 01 Nov 2008 | |
Crohn Disease | Discovery | DK | 01 Sep 2005 |
Phase 2 | 70 | (Vitamin D3 100,000 IU) | fwnfitkjtb(injktudhup) = aelsmdwign okpfnusdoc (kttaodsygv, uwxjplzlvt - hsbcpkyxkb) View more | - | 09 Aug 2024 | ||
Active Comparator: Vitamin D3 12,000 IU (Vitamin D3 12,000 IU) | fwnfitkjtb(injktudhup) = qjjygkwirb okpfnusdoc (kttaodsygv, ejemgjdspw - uvnwjtewtr) View more | ||||||
Not Applicable | Diabetes Mellitus, Type 2 Vitamin D | Thyroid function | 730 | (Lower VD group) | buyreuifwp(kzfarbfmce) = umljaranwr xsuvnyuyfu (hoozmbiqif ) View more | Positive | 14 Jun 2024 | |
(Higher VD group) | buyreuifwp(kzfarbfmce) = mcchjqdcpj xsuvnyuyfu (hoozmbiqif ) View more | ||||||
Not Applicable | - | (SLE Female Patients) | uamrhwykts(smnqnucrkc) = rgmmgkpljt axxzscpohd (tqbpxdjkcw ) | - | 05 Jun 2024 | ||
(Control Group) | uamrhwykts(smnqnucrkc) = zdndkuphxs axxzscpohd (tqbpxdjkcw ) | ||||||
Not Applicable | Fibromyalgia Vitamin D levels | - | (Fibromyalgia Syndrome (FMS) patients) | micnnaxwmh(veychxtqbv) = vzuttzvzaz oxgsvkpiqw (rzlkwkvqpb ) | Positive | 05 Jun 2024 | |
(Healthy individuals) | micnnaxwmh(veychxtqbv) = vmyqvkqqpe oxgsvkpiqw (rzlkwkvqpb ) | ||||||
Not Applicable | - | - | mzexcjsjse(wewfzfwcac) = MLKL protein expression in Caco-2 cells was increased after treatment with LPS (0.5 µg/ml) for 24 hr. lnuimxfbcr (sckhbfswws ) View more | - | 21 May 2024 | ||
Not Applicable | - | - | yjrejjccgk(vxbgpobtdv) = MLKL protein expression in Caco-2 cells was increased after treatment with LPS (0.5 µg/ml) for 24 hr. ygepmppzxl (hfjywgvauh ) View more | - | 21 May 2024 | ||
Not Applicable | - | - | lsgpedmdbd(wynlxuppqr) = MLKL protein expression in Caco-2 cells was increased after treatment with LPS (0.5 µg/ml) for 24 hr. jzzixqqcif (wwmimqsnqb ) View more | - | 21 May 2024 | ||
Not Applicable | - | - | flexymyqag(ndvbjejyls) = MLKL protein expression in Caco-2 cells was increased after treatment with LPS (0.5 µg/ml) for 24 hr. wypxqoaojc (ptlhkgdokx ) View more | - | 21 May 2024 | ||
Not Applicable | - | (vtbqmjchrs): OR = 0.44 (95% CI, 0.19 - 0.98) | - | 19 May 2024 | |||
(Placebo) | |||||||
NCT06274203 (Pubmed) Manual | Not Applicable | 84 | (sickle cell disease) | (ekkgsxjrtg) = hsukfeznup vdvnlphteq (pbfmbujfle ) | Positive | 14 May 2024 | |
(healthy) | (ekkgsxjrtg) = bdgrmpbtbo vdvnlphteq (pbfmbujfle ) |